HCW Biologics (HCWB) Registration filing summary

Offering details and pricing

• Registration covers resale of 218,682 shares of common stock issued July 29, 2026, plus up to 400,000 shares issuable upon exercise of pre-funded warrants and up to 618,682 shares issuable upon exercise of common stock purchase warrants, subject to stockholder approval.

• Shares and warrants were issued pursuant to a Securities Purchase Agreement dated July 29, 2026, with certain accredited investors.

• Common stock purchase warrants require stockholder approval under Nasdaq Listing Rule 5635(d) before issuance.

Management team and governance

• Registration statement signed by CEO Hing C. Wong, CFO Rebecca Byam, Chairman Scott T. Garrett, and directors Lisa M. Giles and Rick S. Greene on August 28, 2026.

• CEO Hing C. Wong is also the founder and principal executive officer.

Underwriters and syndicate

• Placement Agency Agreement dated February 17, 2026, with Maxim Group LLC.

• Placement Agency Agreement with E.F. Hutton & Co. LLC for additional securities.